患有癌症和血液疾病儿童的静脉血栓栓塞症
Venous Thromboembolism in Children with Cancer and Blood Disorders.
作者信息
Ko Richard H, Thornburg Courtney D
机构信息
Genentech, Inc. , South San Francisco, CA , USA.
Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital San Diego , San Diego, CA , USA.
出版信息
Front Pediatr. 2017 Feb 6;5:12. doi: 10.3389/fped.2017.00012. eCollection 2017.
Abstract
Venous thromboembolism (VTE) in children is multifactorial and most often related to a combination of inherited and acquired thrombophilias. Children with cancer and blood disorders are often at risk for VTE due to disease-related factors such as inflammation and abnormal blood flow and treatment-related factors such as central venous catheters and surgery. We will review risk factors for VTE in children with leukemia, lymphoma, and solid tumors. We will also review risk factors for VTE in children with blood disorders with specific focus on sickle cell anemia and hemophilia. We will present the available evidence and clinical guidelines for prevention and treatment of VTE in these populations.
摘要
儿童静脉血栓栓塞症（VTE）是多因素导致的，且通常与遗传性和获得性血栓形成倾向的综合作用有关。患有癌症和血液疾病的儿童由于炎症和血流异常等疾病相关因素以及中心静脉导管和手术等治疗相关因素，常常有发生VTE的风险。我们将回顾白血病、淋巴瘤和实体瘤患儿发生VTE的危险因素。我们还将回顾血液疾病患儿发生VTE的危险因素，特别关注镰状细胞贫血和血友病。我们将展示这些人群中VTE预防和治疗的现有证据及临床指南。
相似文献
1
Venous Thromboembolism in Children with Cancer and Blood Disorders.患有癌症和血液疾病儿童的静脉血栓栓塞症
Front Pediatr. 2017 Feb 6;5:12. doi: 10.3389/fped.2017.00012. eCollection 2017.
2
Risk factors for venous thromboembolism in children.儿童静脉血栓栓塞的危险因素。
Int Angiol. 2004 Sep;23(3):195-205.
3
Overcoming challenges of venous thromboembolism in sickle cell disease treatment.克服镰状细胞病治疗中静脉血栓栓塞症的挑战。
Expert Rev Hematol. 2019 Mar;12(3):173-182. doi: 10.1080/17474086.2019.1583554. Epub 2019 Mar 8.
4
The Impact of Central Venous Catheters on Pediatric Venous Thromboembolism.中心静脉导管对儿童静脉血栓栓塞症的影响。
Front Pediatr. 2017 Jan 23;5:5. doi: 10.3389/fped.2017.00005. eCollection 2017.
5
Hypercoagulable States and Thrombophilias: Risks Relating to Recurrent Venous Thromboembolism.高凝状态与易栓症：与复发性静脉血栓栓塞相关的风险
Semin Intervent Radiol. 2018 Jun;35(2):99-104. doi: 10.1055/s-0038-1642037. Epub 2018 Jun 4.
6
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病治疗期间症状性静脉血栓栓塞的危险因素。
Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11.
7
Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.预防带隧道式中心静脉导管的儿科癌症患者发生静脉血栓栓塞事件的全身治疗。
Cochrane Database Syst Rev. 2013 Sep 11(9):CD009160. doi: 10.1002/14651858.CD009160.pub2.
8
Identification of a "VTE-rich" population in pediatrics - Critically ill children with central venous catheters.儿科“VTE 高风险”人群的鉴定——伴有中心静脉导管的危重症患儿。
Thromb Res. 2018 Jan;161:73-77. doi: 10.1016/j.thromres.2017.11.014. Epub 2017 Nov 22.
9
Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease.对手术和非手术患者进行静脉血栓栓塞性疾病的有效风险分层。
Semin Hematol. 2001 Apr;38(2 Suppl 5):12-9. doi: 10.1016/s0037-1963(01)90094-0.
10
European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the elderly.欧洲围手术期静脉血栓栓塞症预防指南：老年手术。
Eur J Anaesthesiol. 2018 Feb;35(2):116-122. doi: 10.1097/EJA.0000000000000705.
引用本文的文献
1
Development and validation of a nomogram risk prediction model for PICC-related thrombosis in children with hematological malignancies.血液系统恶性肿瘤患儿经外周静脉穿刺中心静脉置管相关血栓形成的列线图风险预测模型的构建与验证
Clin Exp Med. 2025 Jun 10;25(1):195. doi: 10.1007/s10238-025-01707-x.
2
Pharmacokinetics of single-dose rivaroxaban under fed state in obese vs. non-obese subjects: An open-label controlled clinical trial (RIVOBESE-PK).利伐沙班单次给药在肥胖与非肥胖受试者中进食状态下的药代动力学：一项开放标签对照临床试验（RIVOBESE-PK）。
Clin Transl Sci. 2024 Jun;17(6):e13853. doi: 10.1111/cts.13853.
3
Inherited Thrombophilia and Risk of Thrombosis in Children with Cancer: a Single-center Experience.遗传性血栓形成倾向与儿童癌症患者血栓形成风险：单中心经验。
Acta Med Acad. 2023 Dec;52(3):161-168. doi: 10.5644/ama2006-124.430.
4
Incidence and Management of Thromboembolism in Patients with Acute Leukemia.急性白血病患者血栓栓塞的发生率及管理
Indian J Hematol Blood Transfus. 2023 Oct;39(4):642-648. doi: 10.1007/s12288-023-01642-5. Epub 2023 Mar 29.
5
Central venous catheter-associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice.儿童霍奇金淋巴瘤患者中心静脉导管相关并发症：导管选择的意义。
Support Care Cancer. 2022 Oct;30(10):8069-8079. doi: 10.1007/s00520-022-07256-3. Epub 2022 Jul 1.
6
Practical Considerations for Use of Direct Oral Anticoagulants in Children.儿童使用直接口服抗凝剂的实际考量
Front Pediatr. 2022 Apr 1;10:860369. doi: 10.3389/fped.2022.860369. eCollection 2022.
7
Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data.儿科癌症患者的血栓形成与抗凝治疗：真实数据
Cureus. 2021 Dec 1;13(12):e20084. doi: 10.7759/cureus.20084. eCollection 2021 Dec.
8
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.我们如何应对新冠病毒感染和儿童多系统炎症综合征患儿的血栓形成风险。
Pediatr Blood Cancer. 2021 Jul;68(7):e29049. doi: 10.1002/pbc.29049. Epub 2021 May 6.
9
Venous Thromboembolism in Children: From Diagnosis to Management.儿童静脉血栓栓塞症：从诊断到管理。
Int J Environ Res Public Health. 2020 Jul 11;17(14):4993. doi: 10.3390/ijerph17144993.
10
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.镰状细胞病临床试验的终点：肾脏和心肺、治愈和资源匮乏环境。
Blood Adv. 2019 Dec 10;3(23):4002-4020. doi: 10.1182/bloodadvances.2019000883.
本文引用的文献
1
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.在镰状细胞病中凝血酶生成和细胞依赖性高凝状态。
J Thromb Haemost. 2016 Oct;14(10):1941-1952. doi: 10.1111/jth.13416. Epub 2016 Aug 31.
2
Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis C.血友病患者的合并症：疼痛、肥胖和丙型肝炎。
Haemophilia. 2016 Jul;22 Suppl 5:47-53. doi: 10.1111/hae.12996.
3
Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.癌症诊断时的年龄、非 O 血型和门冬酰胺酶治疗与儿科肿瘤患者深静脉血栓形成独立相关：风险模型。
Thromb Res. 2016 Aug;144:27-31. doi: 10.1016/j.thromres.2016.05.015. Epub 2016 May 18.
4
Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters.带隧道式中心静脉导管的儿科肿瘤患者有症状和无症状血栓形成的患病率
Pediatr Blood Cancer. 2016 Aug;63(8):1438-44. doi: 10.1002/pbc.26036. Epub 2016 Apr 29.
5
How I treat patients with inherited bleeding disorders who need anticoagulant therapy.我如何治疗需要抗凝治疗的遗传性出血性疾病患者。
Blood. 2016 Jul 14;128(2):178-84. doi: 10.1182/blood-2015-12-635094. Epub 2016 Apr 22.
6
Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.血友病患者接受大型骨科手术后深静脉血栓形成的前瞻性多中心研究。
Thromb Haemost. 2016 Jul 4;116(1):42-9. doi: 10.1160/TH15-10-0802. Epub 2016 Mar 24.
7
Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ(+) thalassemia genotypes.血红蛋白SC或Sβ(+)地中海贫血基因型成人静脉血栓栓塞的危险因素。
Thromb Res. 2016 May;141:35-8. doi: 10.1016/j.thromres.2016.03.003. Epub 2016 Mar 2.
8
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.抗栓治疗 VTE 疾病：CHEST 指南和专家小组报告。
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
9
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.镰状细胞病的凝血异常：与临床结局的关系及疾病修饰疗法的影响。
Blood Rev. 2016 Jul;30(4):245-56. doi: 10.1016/j.blre.2015.12.003. Epub 2015 Dec 24.
10
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.超越羟基脲：镰状细胞病正在研发中的新药与旧药
Blood. 2016 Feb 18;127(7):810-9. doi: 10.1182/blood-2015-09-618553. Epub 2016 Jan 12.
Zotero 插件